At the conclusion of this activity, participants will be able to:
- Explain the pharmacologic principles which underlie buprenorphine microdosing strategies.
- Differentiate between microdosing and other approaches to opioid agonist treatment (OAT) induction.
- Describe clinical scenarios where microdosing on to buprenorphine may be appropriate.
- List the steps required to initiate buprenorphine/naloxone for opioid use disorder when microdosing.
Dr. Ken Lee, MD MCFP (Addiction Medicine)
London RAAM Clinic
CMHA Mental Health & Addictions Crisis Centre
Operational Stress Injury Clinic (St. Joseph’s Health Care London)
Direct questions about Project ECHO NL: Opioid Use Disorder to:
Knowledge Exchange Facilitator
Provincial Opioid Dependence Treatment Centre of Excellence
This one-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Newfoundland and Labrador Chapter for up to 11 Mainpro+® credits.
Project ECHO NL: Opioid Use Disorder is funded through the Provincial Opioid Dependence Treatment Centre of Excellence (Eastern Health).